Stock RKV RAKOVINA THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Rakovina Therapeutics Inc.

Equities

RKV

CA75103L1013

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 12:33:35 2024-04-18 pm EDT 		5-day change 1st Jan Change
0.095 CAD +5.56% Intraday chart for Rakovina Therapeutics Inc. +11.76% +11.76%
Apr. 09 Rakovina Therapeutics Presents At American Association Of Cancer Research Annual Meeting MT
2023 Rakovina Therapeutics Announces Appointment to Scientific Advisory Board MT

Business Summary

Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is engaged in advancing cancer therapies based on deoxyribonucleic acid (DNA)-damage response technologies. The Company has a pipeline of DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials and obtain marketing approval for cancer therapeutics. The Company’s research programs include kt-2000, kt-3000 and kt-4000. The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating DNA double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cell’s DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.

Managers

Managers TitleAgeSince
Mads Daugaard PSD
 President - 20-12-31
David Hyman DFI
 Director of Finance/CFO - -
John Langlands COO
 Chief Operating Officer - -

Members of the board

Members of the board TitleAgeSince
Alfredo de Lucrezia BRD
 Director/Board Member 57 19-05-05
Jeffrey Bacha CHM
 Chairman 56 20-11-30
Dennis Brown BRD
 Director/Board Member 74 21-03-24
Michael Liggett BRD
 Director/Board Member - 21-03-24

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 70,084,925 38,042,157 ( 54.28 %) 0 54.28 %

Shareholders

NameEquities%Valuation
NewGen Therapeutics, Inc.
37.21 %
24,265,625 37.21 % 2 M $
Alfredo de Lucrezia
7.705 %
5,025,000 7.705 % 371 850 $
Jeffrey Bacha
2.757 %
1,797,857 2.757 % 133 041 $
Dennis Brown
0.9583 %
625,000 0.9583 % 46 250 $
David Hyman
0.4830 %
315,000 0.4830 % 23 310 $
Mads Daugaard
0.1533 %
100,000 0.1533 % 7 400 $
John Langlands
0.0767 %
50,000 0.0767 % 3 700 $
Michael Liggett
0.000000 %
0 0.000000 % - $

Company contact information

Rakovina Therapeutics, Inc.

1008 Beach Avenue Suite 105

V6E 1T7, Vancouver

+

http://www.rakovinatherapeutics.com
address Rakovina Therapeutics Inc.(RKV)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
RAKOVINA THERAPEUTICS INC. Stock Rakovina Therapeutics Inc.
+11.76% 4.57M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.30% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.79% 96.84B
ARGENX SE Stock argenx SE
-0.44% 21.48B
BIONTECH SE Stock BioNTech SE
-18.35% 20.82B
GENMAB A/S Stock Genmab A/S
-7.45% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.81B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.84% 13.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.59% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.86% 11.06B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RKV Stock
  4. Company Rakovina Therapeutics Inc.